Evaluation of mitomycin C (MMC) and Bacillus Calmette-Guerin (BCG) therapies in association with vitamin D levels in enhancement of anti bladder cancer immune response.

Back ground: Bladder cancer (BC) is a complex and multifactorial malignancy. It is the second most common genitourinary cancer. Aim of study: To investigate the influence of vitamin D in association with intravesical immune or chemotherapy in enhancement of antitumor immunity in bladder cancer patients (BC), Material and methods: 89 subjects (59 cases and 30 controls) were enrolled in current study. Patients were categorized into three groups based on their treatment: patient control (PC) those who were newly diagnosed untreated patients, those treated with mitomycine C (MMC) intravesical chemotherapy, and those treated with (BCG) intravesical immunotherapy. Serum levels of VD, TNF-?, TNF-?, and IFN-? were measured using ELISA technique in each of studied groups. Results: Serum levels of VD showed insignificant elevations in each of PC group , treated patients with MMC group, and treated BCG group compared with HC group. Serum levels of TNF-?, statistical analysis have shown significant dropping in each of PC, MMC, and BCG groups compared with HC group. Significant dropping in serum levels of TNF-? in PC group and insignificant elevation in MMCgroup were recorded, while there was insignificant dropping in BCG group compared with HC group. Serum levels of INF-? revealed insignificant dropping in PC group and insignificant elevation in each of MMC and BCG groups compared with HC group. Conclusion: serum levels of VD in both of cases and controls were within insufficient status, so cannot evaluate the association of VD status with BC incidence. Immunotherapy (BCG) was more efficient than chemotherapy (MMC) in enhancement of antitumor immune response.